Catégorie : Cannabis et santé mentale

How Adolescents with Autism Spectrum Disorder (ASD) Spontaneously Attend to Real-World Scenes : Use of a Change Blindness Paradigm, Michal Hochhauser et al., 2018

How Adolescents with Autism Spectrum Disorder (ASD) Spontaneously Attend to Real-World Scenes : Use of a Change Blindness Paradigm Michal Hochhauser, Adi Aran, Ouriel Grynszpan Journal of Autism and Developmental Disorders, 2018, 48, 502–510 DOI 10.1007/s10803-017-3343-6 https://www.researchgate.net/publication/320647151_How_Adolescents_with_Autism_Spectrum_Disorder_ASD_Spontaneously_Attend_to_Real-World_Scenes_Use_of_a_Change_Blindness_Paradigm [accessed Jul 16 2019].   Abstract Visual attention of adolescents with autism spectrum disorder (ASD) was assessed using a change blind-ness paradigm. Twenty-five adolescents with ASD aged 12–18 years and 25 matched typically developing (TD) adolescents viewed 36 pairs of digitized real-world images. Each pair of images was displayed in a ‘flicker paradigm’ whereby a particular item alternately appeared and disappeared. This item was either a central or a marginal [...]

Lire la suite

Le cannabidiol en traitement “anti-addictif” chez les patients alcooliques : l’étude CARAMEL, François Bailly – Benjamin Rolland, RESPADD – GRECC, juin 2019

Le cannabidiol en traitement «anti-addictif» chez les patients alcooliques : l’étude CARAMEL PHRC-N 2018 n°0198 Investigateur principal B. Rolland François Bailly, service d’hépatologie et d’addictologie, Hôpital de la Croix Rousse, Lyon.   Le cannabidiol en traitement « anti-addictif » chez les patients alcooliques : l’étude CARAMEL François Bailly Hôpital de la Croix-Rousse, Lyon Le protocole CARAMEL, qui devrait démarrer début 2020, est destiné à étudier l’intérêt du cannabidiol dans la dépendance alcoolique. Le projet d’étude est centré sur les effets du CBD sur le système nerveux central et les neuroprotecteurs et antioxydants, qui ont un impact sur la toxicité de l’alcool au niveau du cerveau et du foie, [...]

Lire la suite

Prescribing Health Care Providers’ Attitudes, Experiences, and Practices Surrounding Cannabis Use in Patients with Anxiety Disorders and Post-Traumatic Stress Disorder, Jake Rosenberg et al., 2019

Prescribing Health Care Providers’ Attitudes, Experiences, and Practices Surrounding Cannabis Use in Patients with Anxiety Disorders and Post-Traumatic Stress Disorder Jake Rosenberg, Mallory J.E. Loflin, Yasmin L. Hurd, and Marcel O. Bonn-Miller Cannabis and Cannabinoid Research, 2019, Volume 4, Number 2, DOI: 10.1089/can.2018.0008   Abstract Background : Preliminary evidence suggests that certain cannabinoids may be beneficial for the treatment of anxiety and post-traumatic stress disorder (PTSD). However, it is unclear whether prescribing health care professionals view medicinal cannabis as a safe and effective option for treatment of these disorders. Methods : Three hundred fifty-two prescribing health care professionals across the United States completed an online survey assessing [...]

Lire la suite

How effective and safe is medical cannabis as a treatment of mental disorder ? A systematic review, Eva HOCH et al., 2019

How effective and safe is medical cannabis as a treatment of mental disorder ? A systematic review HOCH E., NIEMANN D., von KELLER R., SCHNEIDER M., FRIEMEL C.M., PREUSS U.W., HASAN A., POGARELL O. European Archives of Psychiatry and Clinical Neuroscience, 2019 https://doi.org/10.1007/s00406-019-00984-4   Abstract We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006—August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general social anxiety, posttraumatic stress disorder, anorexia nervosa, [...]

Lire la suite

Evidences for the Anti-panic Actions of Cannabidiol, Vanessa P. Soares and Alline C. Campos, 2017

Evidences for the Anti-panic Actions of Cannabidiol Vanessa P. Soares and Alline C. Campos Current Neuropharmacology, 2017, 15, 291-299 DOI : 10.2174/1570159X14666160509123955   Abstract : Background : Panic disorder (PD) is a disabling psychiatry condition that affects approximately 5% of the worldwide population. Currently, long-term selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for PD; however, the common side-effect profiles and drug interactions may provoke patients to abandon the treatment, leading to PD symptoms relapse. Cannabidiol (CBD) is the major non-psychotomimetic constituent of the Cannabis sativa plant with antianxiety properties that has been suggested as an alternative for treating anxiety disorders. The aim of the [...]

Lire la suite

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial, Philip McGuire et al.,

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial Philip McGuire, F.R.C.Psych., F.Med.Sci., Philip Robson, M.R.C.P., F.R.C.Psych., Wieslaw Jerzy Cubala, M.D., Ph.D., Daniel Vasile, M.D., Ph.D., Paul Dugald Morrison, Ph.D., M.R.C.Psych., Rachel Barron, B.Vet.Med., M.R.C.V.S., Adam Taylor, Ph.D., Stephen Wright, F.R.C.P.(Edin), F.F.P.M. American Journal of Psychiatry, 2018, 175, 225–231. doi: 10.1176/appi.ajp.2017.17030325   Objective : Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. Method : In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 mg/day; [...]

Lire la suite

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence, Cathrin Rohleder et al., 2016

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence Cathrin Rohleder, Juliane K. Müller, Bettina Lange and F. M. Leweke Frontiers in Pharmacology, 2016, Volume 7, Article 422. doi: 10.3389/fphar.2016.00422   There is urgent need for the development of mechanistically different and less side-effect prone antipsychotic compounds. The endocannabinoid system has been suggested to represent a potential new target in this indication. While the chronic use of cannabis itself has been considered a risk factor contributing to the development of schizophrenia, triggered by the phytocannabinoid delta-9-tetra-hydro-cannabinol (19-THC), cannabidiol, the second most important phytocannabinoid, appears to have no psychotomimetic potential. [...]

Lire la suite

Therapeutic Potential of Cannabinoids in Psychosis, Leweke F.M. et al., 2016

Therapeutic Potential of Cannabinoids in Psychosis. Leweke F.M., Mueller J.K., Lange B., Rohleder C. Biological Psychiatry, 2016, 79, (7) 604-612. doi: 10.1016/j.biopsych.2015.11.018.   Abstract Over recent years, the interest in the endocannabinoid system (ECS) as a new target for the treatment of schizophrenia has evolved. The ECS represents one of the most relevant neurotransmitter systems in the brain and mainly fulfills a homeostatic role in terms of neurotransmission but also with respect to inflammatory processes. Two main approaches to the modulation of endocannabinoid functioning have been chosen so far. First, the selective blockade or inverse agonism of the type 1 cannabinoid receptor has been tested for [...]

Lire la suite

Cannabidiol for the Treatment of Drug Use Disorders, R.G. dos SANTOS, J.E.C. HALLAK, W. ZUARDI, J.A. de SOUZA, 2017

Chapter 97 - Cannabidiol for the Treatment of Drug Use Disorders R.G. dos SANTOS, J.E.C. HALLAK, W. ZUARDI, J.A. de SOUZA in "Handbook of Cannabis and Related Pathologies". "Biology, Pharmacology, Diagnosis, and Treatment", 2017, Pages 939-946 https://doi.org/10.1016/B978-0-12-800756-3.00113-7 Abstract The problematic use of psychoactive substances like alcohol, cannabis, cocaine, amphetamines, heroin, and nicotine carry a series of health, economic, and social costs to individuals and society. Although pharmacological treatments for alcohol, heroin, and nicotine abuse or dependence are available, there is no approved medication for the treatment of cannabis and stimulant dependence. Cannabidiol (CBD), a nonpsychotomimetic cannabinoid present in the cannabis plant, has anxiolytic, antipsychotic, antiepileptic, [...]

Lire la suite

Cannabidiol and Canabis Use Disorder, María S. García-Gutiérrez et al., 2018

Cannabidiol and Canabis Use Disorder María S. García-Gutiérrez, Francisco Navarrete, Adrián Viudez-Martínez, Ani Gasparyan, Esther Caparrós, Jorge Manzanares Chapter, In book : "Cannabis Use Disorders", 2018, pp 31-42 DOI: 10.1007/978-3-319-90365-1_5 Abstract Cannabis use disorders (CUD) represent a serious public health problem in occidental societies. Despite their devastating social, health, and economic impact, to date no pharmacological treatment has been approved for the clinical management of cannabis dependence. Cannabidiol (CBD), one of the main compounds—together with Δ9-THC—present in the plant Cannabis sativa, has been reported to possess anxiolytic, antidepressant, and antipsychotic-like effects and neuroprotective properties. And, contrary to Δ9-THC, CBD does not appear to have addictive properties. Taken [...]

Lire la suite